乙型肝炎肝硬化患者血清IL-10和可溶性细胞间黏附分子-1水平及其对疾病预后的判断价值*

doi:10.3969/j.issn.1672-5069.2019.04.025

摘要/Abstract

摘要： 目的分析比较乙型肝炎肝硬化患者血清细胞因子水平变化及其与疾病进展的关系。方法 2014年9月~2016年8月我院收治的79例乙型肝炎肝硬化患者,其中Child-Pugh A级31例,B级25例,C级23例,另选体检健康人23例作为对照,采用ELISA法检测血清IL-2、IL-6、IL-10和可溶性细胞间黏附分子-1（sICAM-1）。结果代偿期肝硬化和失代偿期肝硬化患者血清IL-10水平水平分别为（43.5±8.4） g/L和（55.8±6.1） g/L,显著低于健康人【（247.1±43.4） g/L,P<0.01】,而血清IL-2、IL-6和sICAM-1水平分别为（148.1±21.3） g/L、（43.5±8.4） g/L和（298.5±85.7） ng/mL,和（180.6±17.1） g/L、（55.8±6.1） g/L和（685.4±164.8） ng/mL,均显著高于健康人【（22.6±6.0） g/L、（6.6±1.5） g/L和（158.7±21.5） ng/mL,P<0.05】;23例Child-Pugh C级患者血清IL-10水平为（84.3±11.4） g/L,显著低于31例Child-Pugh A级或25例Child-Pugh B级【分别为（121.3±14.6） g/L和（101.4±12.6） g/L;P<0.05】,而血清IL-2、IL-6和sICAM-1水平分别为（182.7±31.4） g/L、（57.3±7.3） g/L和（665.0±135.5） ng/mL,显著高于Child-Pugh A级或Child-Pugh B级【分别为（138.4±19.6） g/L、（42.4±6.6） g/L和（398.7±103.3） ng/mL,和（157.7±22.3） g/L、（49.9±6.2） g/L和（509.6±122.9） ng/mL,P<0.05】;肝硬化患者发生自发性细菌性腹膜炎、肝性脑病或消化道出血时,血清IL-10水平会进一步降低,而血清IL-2、IL-6和sICAM-1水平则进一步升高。结论乙型肝炎肝硬化患者血清细胞因子水平会随着疾病的变化而改变,了解这些变化对指导诊疗可能有帮助。

关键词: 肝硬化, 乙型肝炎, 可溶性细胞间黏附分子-1, 白细胞介素-10

Abstract: Objective To investigate the changes of serum IL-10 and soluble intercellular adhesion molecule-1 （sICAM 1） levels in patients with hepatitis B-induced liver cirrhosis （LC）.Methods A total of 79 patients with hepatitis B-induced LC, including 31 with Child-Pugh class A, 25 with Child-Pugh class B and 23 with Child-Pugh class C,were enrolled in our hospital between September 2014 and August 2016, and 23 healthy persons were selected as control. Serum interleukin（IL）-2,IL-6,IL-10 and sICAM 1 levels were detected by enzyme-linked immunosorbent assay.Results Serum IL-10 levels in patients with compensated and decompensated LC were （43.5±8.4） g/L and （55.8±6.1） g/L,respectively,much lower than （247.1±43.4） g/L （P<0.01） in healthy persons,while serum IL-2,IL-6 and sICAM-1 levels were （148.1±21.3） g/L,（43.5±8.4） g/L and （298.5±85.7）ng/mL,and （180.6±17.1） g/L,（55.8±6.1） g/L and （685.4±164.8） ng/mL, respectively,significantly higher than （22.6±6.0）g/L,（6.6±1.5） g/L and （158.7±21.5） ng/mL in healthy control （P<0.05）;serum IL-10 level in 23 patients with Child-Pugh class C was（84.3±11.4） g/L,much lower than（121.3±14.6） g/L in 31 patients with Child-Pugh class A or（101.4±12.6） g/L in 25 with Child-Pugh class B （P<0.05）,while serum IL-2,IL-6 and sICAM-1 levels were （182.7±31.4） g/L,（57.3±7.3） g/L and（665.0±135.5） ng/mL,much higher than （138.4±19.6） g/L,（42.4±6.6） g/L and （398.7±103.3） ng/mL,in patients with Child-Pugh class A or （157.7±22.3） g/L,（49.9±6.2） g/L and （509.6±122.9） ng/mL in patients with Child-Pugh class B（all P<0.05）;serum IL-10 levels decreased,while serum IL-2,IL-6 and sICAM-1 levels increased in patients with complications such as spontaneous bacterial peritonitis,hepatic encephalopathy or gastrointestinal bleeding. Conclusion Serum cytokine levels change as liver functions deteriorate, which might be helpful for clinicians to make managements in time in clinical practice.

Key words: Liver cirrhosis, Hepatitis B, Soluble intercellular adhesion molecule-1, Interleukin-10

金军, 宋震宇, 刘吉祥. 乙型肝炎肝硬化患者血清IL-10和可溶性细胞间黏附分子-1水平及其对疾病预后的判断价值^*[J]. 实用肝脏病杂志, 2019, 22(4): 549-552.

Jin Jun, Song Zhenyu, Liu Jixiang. Changes of serum IL-10 and soluble intercellular adhesion molecule-1 levels in patients with hepatitis B-induced liver cirrhosis[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 549-552.

参考文献

[1] Wang X,Lin SX,Tao J,et al.Study of liver cirrhosis over ten consecutive years in southern China. World J Gastroenterol,2014,20(37):13546-13555.
[2] 程丹,邵志林,吴亮,等. 乙型肝炎肝硬化和肝癌患者血清铁蛋白检测的意义. 实用肝脏病杂志,2016,19(6):736-737.
[3] Angulo P,Kleiner DE,Damlarsen S,et al.Liver fibrosis,but no other histologic features,is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology,2015,149(2):389-397,e10.
[4] Qi X,Li H,Jiang C,et al.Serum liver fibrosis markers for predicting the presence of gastroesophageal varices in liver cirrhosis:a retrospective cross-sectional study. Gastroenterol Res Prac,2015,2015(3):1-6.
[5] Reininghaus EZ,Lackner N,Birner A,et al.Extracellular matrix proteins matrix metallopeptidase 9(MMP9) and soluble intercellular adhesion molecule 1(sICAM-1) and correlations with clinical staging in euthymic bipolar disorder. Bipolar Disord,2016,18(2):155.
[6] Gudowska M,Gruszewska E,Panasiuk A,et al.Hyaluronic acid concentration in liver diseases. Clin Exp Med,2016,16(4):523-528.
[7] 连佳,韩涛,向慧玲,等. 恩替卡韦与阿德福韦酯单药治疗慢性乙型肝炎相关性肝病患者240周的随机对照研究. 中华肝脏病杂志,2015,23(10):733-737.
[8] Hanai T,Shiraki M,Nishimura K,et al.Sarcopenia impairs prognosis of patients with liver cirrhosis. Nutrition,2015,31(1):193-199.
[9] Abbas M,Abbas Z.Serum cholinesterase:A predictive biomarker of hepatic reserves in chronic hepatitis D. World J Hepatol,2017,9(22):967-972.
[10] Cheng BN,Jin YL,Chen BQ,et al.Serum cholinesterase:a potential assistant biomarker for hand,foot,and mouth disease caused by enterovirus 71 infection. Infect Dis Poverty,2016,5(1):27.
[11] Ramachandran J,Sajith KG,Priya S,et al.Serum cholinesterase is an excellent biomarker of liver cirrhosis. Trop Gastroenterol,2014,35(1):15.
[12] George TR,Ju MM,Heon KJ,et al.Effectiveness of losartan-loaded hyaluronic acid (ha) micelles for the reduction of advanced hepatic fibrosis in c3h/hen mice model. PLoS One,2015,10(12):e0145512.
[13] Yang JA,Kong WH,Sung DK,et al.Hyaluronic acid-tumor nec-rosis factor-related apoptosis-inducing ligand conjugate for targeted treatment of liver fibrosis. Acta Biomater,2015,12(1):174.
[14] 童芳芳. 肝硬化并发自发性细菌性腹膜炎患者血清与腹水TNF-α、IL-6和IL-8水平差异比较. 实用肝脏病杂志, 2015,18(2):191-192.
[15] Gheorghe L,Rugin S,Dumitru IM,et al.HLA class Ⅱ alleles in Romanian patients with chronic hepatitis C. Germs,2015,5(2):44-49.
[16] Shim HJ,Lee R,Shin MH,et al.Association between abo genotype and risk of hepatocellular carcinoma in Koreans. Asian Pac J Cancer Prev,2015,16(7):2771-2775.
[17] Casrouge A,Decalf J,Ahloulay M,et al.Evidence for an antagonist form of the chemokine CXCL10 in patients chronically infected with HCV. J Clin Invest,2011,121(1):308-317.
[18] Ingiliz P,Mayr C,Obermeier M,et al.Persisting hepatitis e virus infection leading to liver cirrhosis despite recovery of the immune system in an HIV-infected patient. Clin Res Hepatol Gastroenterol,2016,40(3):e23-e25.
[19] Yadav S,Goel A,Saraswat V,et al.Evaluation of cognitivity,proinflammatory cytokines,and brain MRI in minimal hepatic encephalopathy induced by cirrhosis and ehpvo. J Gastroenterol Hepatol,2016,31(12):1986.
[20] Angulo P,Kleiner DE,Damlarsen S,et al. Liver fibrosis,but no other histologic features,is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology,2015,149(2):389-397.e10.

乙型肝炎肝硬化患者血清IL-10和可溶性细胞间黏附分子-1水平及其对疾病预后的判断价值^*

Changes of serum IL-10 and soluble intercellular adhesion molecule-1 levels in patients with hepatitis B-induced liver cirrhosis

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	庄莹, 林志辉. 肝硬化并发门静脉血栓临床表现和诊断进展[J]. 实用肝脏病杂志, 2019, 22(6): 765-767.
[2]	朱凌云, 张茂海, 崔莎莎, 张秋萍. 慢性乙型肝炎患者血清IL-12、IL-18水平和外周血单个核细胞FOXp3基因水平研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 816-819.
[3]	石莹莹, 王元喜. 替比夫定联合阿德福韦酯治疗慢性乙型肝炎患者效果及其对肾功能的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 820-823.
[4]	闵峰, 黄文琪, 吴卫兵, 张丽, 范荣华. 慢性乙型肝炎患者血清脂肪细胞因子水平变化及其临床意义^*[J]. 实用肝脏病杂志, 2019, 22(6): 824-827.
[5]	张迎明, 申爽, 田飞, 孙园园. IFNL4和IL-28B基因多态性检测评估慢性乙型肝炎患者抗病毒治疗应答价值分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 828-831.
[6]	吴海义, 陈建新. 四种诊断模型诊断乙型肝炎病毒携带者肝纤维化的效能分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 832-835.
[7]	马丽英, 沈利娟. 妊娠后期应用替诺福韦治疗血清HBV高载量孕妇阻断HBV母婴传播的疗效及安全性分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 836-839.
[8]	杨才勇, 陈娜, 李奎, 江自成, 卜蓉蓉. 慢性丙型肝炎和丙型肝炎肝硬化患者外周血Treg和Th17水平变化临床意义探讨^*[J]. 实用肝脏病杂志, 2019, 22(6): 868-871.
[9]	朱娅鸽, 刘锦峰. 丁二磺酸腺苷蛋氨酸联合复方甘草酸苷治疗酒精性肝硬化患者疗效及其对血清BGP水平的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 872-875.
[10]	武丹, 马向鹰. 非酒精性脂肪性肝病肝硬化患者胰岛素抵抗水平与颈动脉硬化程度和左心室功能研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 876-879.
[11]	陈梅梅, 段晓燕, 曹海霞, 丁雯瑾. 复方鳖甲软肝片治疗原发性胆汁性肝硬化患者疗效分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 880-883.
[12]	刘李, 杨烈, 陈海洋, 何承俊, 王建宇, 陈廷昊. 肝硬化门静脉高压症并发脾动脉盗血综合征患者脾切除联合贲门周围血管离断术后门脉血流动力学的变化^*[J]. 实用肝脏病杂志, 2019, 22(6): 884-887.
[13]	何志安, 余丽萍, 赖江琼, 黄思付. ARFI评估肝硬化并发食管胃底静脉曲张患者出血和门静脉血栓的价值分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 888-891.
[14]	李传杰, 徐静, 王亮亮, 潘劲劲, 刘波. 恩替卡韦治疗慢性乙型肝炎患者血清HBsAg变化与病毒学应答的相关性研究[J]. 实用肝脏病杂志, 2019, 22(6): 928-929.
[15]	杜科业, 杨东亮, 刘嘉. 慢性乙型肝炎与调节性T细胞研究进展^*[J]. 实用肝脏病杂志, 2019, 22(5): 613-616.